1 / 16

Prof. Massimo Colombo Co-Chairman Department of Medicine, Head Division of Gastroenterology

Paris Hepatitis Conference. Paris, 19th-20th January 2009. Screening and diagnosis of hepatocellular carcinoma. Prof. Massimo Colombo Co-Chairman Department of Medicine, Head Division of Gastroenterology Fondazione IRCCS Policlinico, Mangiagalli e Regina Elena

grosse
Download Presentation

Prof. Massimo Colombo Co-Chairman Department of Medicine, Head Division of Gastroenterology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Paris Hepatitis Conference Paris, 19th-20th January 2009 Screening and diagnosis of hepatocellular carcinoma Prof. Massimo Colombo Co-Chairman Department of Medicine, Head Division of Gastroenterology Fondazione IRCCS Policlinico, Mangiagalli e Regina Elena Università degli Studi di Milano Milano

  2. Increasing Incidence of Early Stage HCC in the Referral CentersThe Experience in Japan Ogaki Municipal Hospital, Japan. Data-base: 1968-2004. 1641 patients with a HCC Curative treatments in 1067 (65%) Toyoda H et al, Clin Gastroenterol Hepatol 2006;4:1170-1176

  3. Groups of Patients for whom Surveillance Is Recommended 1EASL Conference, Bruix et al J Hepatol 2001;35:421-430 ; 2AASLD Practice Guidelines, Bruix & Sherman Hepatology 2005;42:1208-1236 3JSH Clinical Practice Guidelines for HCC, Makuuchi et al Hepatol Res 2008;38:37-51

  4. Are Surveillance Programs Improved by Patients Stratification by Clinical and Histological Scores? 1 Hepatology 1996;23:1112-1118; 2 Hepatology 2003;37:520-527

  5. Studies Comparing the Diagnostic Accuracy and Outcome of Surveillance with Different Screening Intervals 1 Blood 2003;102:78-82; 2 J Hepatol 2006;44 Suppl 2:S4; 3 ILCA Proceedings Barcelona 5-7 October 2007, 11

  6. Radiological Diagnosis of Hepatocellular Carcinoma in Patients With CirrhosisEASL/AASLD Guidelines Imaging techniques contrast-enhanced US, contrast-enhanced spiral CT and gadolinium-enhanced MRI 1-2 cm node two imaging techniques showing hyperenhanced node in the arterial phase and hypoenhanced node in the portal phase (wash-out) > 2 cm node one imaging technique Prospective validation* 89 patients with a 5-20 mm nodule Sensitivity 33% CE – US + MRI Specificity 100% EASL, AASLD & JSH Conference, Barcelona 2005; AASLD Practice Guidelines 2007; *Forner et al 2008

  7. The Diagnosis of HCC at Two Coincidental Imaging Techniques in 55 1-2 cm Liver Nodules in 54 Cirrhotic Patients Early arterial hypervascularization Portal/venous wash-out Combined Sangiovanni et al 2009 submitted

  8. Number and Estimated Cost of the Stepwise Investigations for the Assessment of 55 1-2 cm  Nodules in 54 Cirrhotic Patients p=0.031 Sangiovanni et al 2009 submitted

  9. The Importance of Liver Biopsy To Discriminate Dysplastic Nodes (DN) from Early Hepatocellular Carcinoma (HCC)

  10. The Importance of Liver Biopsy To Identify a Very Early HCC Distinctly nodular, early Vaguely nodular, very early cm cm Hypervascular on contrast imaging Hypovascular on contrast imaging Very early HCC: 17% of all HCCs 1-2 cm in size (Bolondi et al 2005) 5-yr survival after resection: 93% vs 54% early (Takayama et al 1998) Nakashima O et al, Hepatology 1995;22:101-105; Kojiro M et al, Sem Liver Dis 2005;25:133-142

  11. A RCT of Population-based Screening for HCC: The Importanceof Early Diagnosis for Improving Liver-Related Mortality RCT in urban Shanghai, abdominal US+AFP every 6 months, HBV / chronic hepatitis Limitations: patients with cirrhosis unknown, suboptimal compliance (58%), no transplant Findings Screened group Control group (pp x yr = 38,444) (pp x yr = 41,077) HCC occurrence Cases 86 67 Early cancer 39 0 Total incidence (per 100,000) 223.7 163.1 Rate ratio (95% CI) 1.37 (0.99, 1.89) reference Deaths from HCC Deaths 32 54 Total mortality (per 100,000) 83.2 131.5 Rate ratio (95% CI)0.63 (0.41, 0.98) reference Zhang BH, J Cancer Res Clin Oncol 2004;130:417-422

  12. Clinic-based Surveillance for HCC in Cirrhotics: The Importance of Treatment Refinement for Improving Liver-Related Mortality A prospective cohort study of 447 patients with compensated cirrhosis of mixed etiology in Milan under surveillance with abdominal US and AFP. Outcomes 1987-91 1992-96 1997-2001 p-value HCC, No. HCC size, cm Radical treatments Mortality in treated Mortality in untreated Overall mortality 52 3.7 (1.5-8) 28% 34% 69% 45% 37 3.0 (1.5-6.0) 38% 28% 100% 37% 23 2.2 (1.4-3.1) 43% 5% 92% 10% = 0.02 = 0.02 = 0.024 n.s. = 0.0009 Sangiovanni A, et al Gastroenterology 2004;126:1005-1014

  13. Improved Survival of HCC Patients Is More Influenced by Early Detection Than by Improvement of Medical Care NH Taiwan University Hospital. Data-base: 1988-1998: A=1989-1993, B=1994-1998 3,445 patients with HCC. 5-yr survival: 29% (A) vs 35% (B), p=0.01. Chie WC, et al J Evaluat Clin Pract 2007;13:79-85

  14. Markov Decision Models to Simulate Cost-utility Ratio of Surveillance According to AASLD/EASL Guidelines

  15. Conclusions • According to EASL/AASLD recommendations, patients at high risk for developing HCC should be entered into surveillance programs (Level 1). • In most industrialized countries > 50% of the patients with a diagnosis of HCC have been treated with screening and found eligible to radical treatments. • The disparity in outcomes between patients diagnosed with an early HCC compared to those with a more advanced tumor, strongly supports screening for HCC. • Though surveillance is appropriate when the risk of developing HCC is 1.5% or greater, the cost-effectiveness and the cost-benefit ratios of surveillance vary considerably depending on screening strategies and therapeutic options available.

  16. Clinic-based Surveillance Programmes: The Compliance of Patients with Compensated Cirrhosis Thompson Coon J et al Health Technol Assess 2007;11:No. 34

More Related